1.77
-0.01(-0.56%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.75 |
| Day High | 1.83 |
| Day Low | 1.73 |
| 52-Week High | 4.35 |
| 52-Week Low | 1 |
| Volume | 65,395 |
| Average Volume | 146,468 |
| Market Cap | 40.64M |
| PE | -0.56 |
| EPS | -3.18 |
| Moving Average 50 Days | 2.14 |
| Moving Average 200 Days | 2.15 |
| Change | -0.01 |
If you invested $1000 in Celularity Inc. (CELU) since IPO date, it would be worth $18.06 as of November 11, 2025 at a share price of $1.77. Whereas If you bought $1000 worth of Celularity Inc. (CELU) shares 5 years ago, it would be worth $17.18 as of November 11, 2025 at a share price of $1.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE,
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
GlobeNewswire Inc.
Oct 14, 2025 12:45 PM GMT
First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified stem cell therapy under Florida statute (§ 458.3245
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by N